Outpatient Management of CAR-T and Teclistamab for Patients with Lymphoma and Multiple Myeloma

被引：7

作者：

Bansal, Radhika ^{[1
]}

Paludo, Jonas ^{[2
]}

Corraes, Andre ^{[2
]}

Spychalla, Megan ^{[2
]}

Haugen, Kelsey ^{[2
]}

Khurana, Arushi ^{[2
]}

Hampel, Paul J. ^{[2
]}

Durani, Urshila ^{[3
]}

Dingli, David ^{[2
]}

Hayman, Suzanne R. ^{[2
]}

Kapoor, Prashant ^{[2
]}

Wang, Yucai ^{[3
]}

Binder, Moritz ^{[2
]}

Kenderian, Saad S. ^{[3
]}

Kourelis, Taxiarchis ^{[3
]}

Kumar, Shaji Kunnathu ^{[3
]}

Warsame, Rahma M. ^{[4
]}

Bennani, N. Nora ^{[2
]}

Gertz, Morie A. ^{[5
]}

Johnston, Patrick B. ^{[3
]}

Ansell, Stephen M. ^{[3
]}

Lin, Yi ^{[1
]}

机构：

[1] Mayo Clin, Canc Ctr, Rochester, MN USA

[2] Mayo Clin, Rochester, MN USA

[3] Mayo Clin, Div Hematol, Rochester, MN USA

[4] Mayo Clin, Div Hematol, Dept Internal Med, Rochester, MN USA

[5] Mayo Clin, Div Hematol, Dept Med, Rochester, MN USA

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-187186

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：4

共 50 条

[21] Quality of life pattern in patients with multiple myeloma infused with CAR-T therapy
Andersson-Vila, C. I.
Montoro-Lorite, M.
Oliver-Caldes, A.
Ortiz-Maldonado, V.
Fernandez-de larrea, C.
BONE MARROW TRANSPLANTATION, 2022, 57 (SUPPL 1) : 427 - 427
[22] Inpatient vs Outpatient Use of Teclistamab in Multiple Myeloma
Chari, Ajai
Callander, Natalie
Pianko, Matthew James
Schmidt, Timothy
Landgren, C. Ola
Costello, Caitlin
ONCOLOGY-NEW YORK, 2024, 38 (02):
[23] Clinical outcomes among multiple myeloma and lymphoma patients taking beta-blockers undergoing CAR-T therapy
Balandan, Kristina
Hwa, Yi
Bansal, Radhika
Khurana, Arushi
Johnston, Patrick
Ansell, Stephen
Bennani, Nora
Binder, Moritz
Dingli, David
Gertz, Morie
Haymann, Suzanne
Kapoor, Prashant
Kourelis, Taxiarchis
Kumar, Shaji
Paludo, Jonas
Warsame, Rahma
Wang, Yucai
Cook, Joselle
Durani, Urshila
Lin, Yi
Dispenzieri, Angela
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S34 - S34
[24] CAR-T cells immunotherapy in multiple myeloma: Present and future
Ferment, Benoit
Arnulf, Bertrand
BULLETIN DU CANCER, 2021, 108 (10) : S65 - S72
[25] Multiple myeloma: soon CAR-T cells off the shelf?
不详
TRANSFUSIONSMEDIZIN, 2023, 13 (03) : 114 - 115
[26] Current Status of CAR-T Cell Therapy in Multiple Myeloma
Reguera-Ortega, Juan Luis
Garcia-Guerrero, Estefania
Perez-Simon, Jose Antonio
HEMATO, 2021, 2 (04): : 660 - 671
[27] Decentralised, point-of-care CAR-T for multiple myeloma
Anguille, Sebastien
Krekelbergh, Laurens
LANCET ONCOLOGY, 2023, 24 (08): : 828 - 830
[28] Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma
Jasinski, Marcin
Basak, Grzegorz W.
Jedrzejczak, Wieslaw W.
FRONTIERS IN IMMUNOLOGY, 2021, 12
[29] CAR-T TREATMENT COSTS BEYOND THERAPY ACQUISITION COSTS IN MULTIPLE MYELOMA PATIENTS
Jagannath, S.
Joseph, N.
Crivera, C.
Jackson, C. C.
Valluri, S.
Cost, P.
Phelps, H.
Slowik, R.
Klein, T. M.
Smolen, L.
Yu, X.
Cohen, A.
VALUE IN HEALTH, 2022, 25 (07) : S348 - S348
[30] Prognostic markers for CAR-T cell therapy in patients with relapsed/refractory multiple myeloma
Liu, Yang
Yan, Zhiling
Wu, Qingyun
Chen, Chong
Cao, Jiang
Li, Zhenyu
Xu, Kailin
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S49 - S49

← 1 2 3 4 5 →